Delivery Order SPE2DB24D9238-SPE2DB25FDRCJ
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $4,642.20 by the Defense Logistics Agency (DLA) on September 4, 2025. The delivery order is for Xolair 150 mg/ml syringes, with an ultimate completion date of September 25, 2025. This award carries no set-aside designation, allowing the vendor to compete on equal footing in the federal procurement marketplace. The place of...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order valued at approximately $142,000 by the Defense Logistics Agency (DLA) for XOLAIR 150 mg/ml syringes. The contract is firm fixed-price with an ultimate completion date of September 16, 2025, and was awarded on August 25, 2025, without set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order valued at $1,547.40 by the Defense Logistics Agency (DLA) for XOLAIR 150 MG/ML Syringe. This firm fixed-price delivery order, issued on September 12, 2025, with an ultimate completion date of October 3, 2025, is being performed at the contractor's location in Park Ridge, Illinois. The award carries no set-aside designation, allowing DMS...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $1,547.40 by the Defense Logistics Agency (DLA) on September 12, 2025, for the supply of Xolair 150 mg/ml syringes. This firm fixed-price delivery order, with an ultimate completion date of October 3, 2025, is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA under the SPE2DB program, valued at...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $4,642.20 by the Defense Logistics Agency's Medical Supply Chain for the supply of Xolair 150 mg/ml syringes. The award, issued on August 29, 2025, with an ultimate completion date of September 22, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger single-award...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $37,137.60 by the Defense Logistics Agency (DLA) on August 21, 2025. The delivery order, which carries no set-aside designation, is for Xolair 150 mg/ml syringes with an ultimate completion date of September 12, 2025. This award represents a single delivery order issued under DMS Pharmaceutical Group's larger Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a firm fixed-price delivery order valued at $5,581.44 by the Defense Logistics Agency (DLA) for the supply of Xolair 300 mg/2 ml syringes. The delivery order, issued on September 10, 2025, carries an ultimate completion date of October 1, 2025, with no set-aside designation applied. This award represents a specific task order issued under DMS Pharmaceutical...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency on September 17, 2025, for Xolair 150 mg/mL syringes, with a ceiling value of $1,547.40. This firm fixed-price delivery order is part of DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract with the DLA under the SPE2DB program, valued at approximately $500 million and valid through November...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order by the Defense Logistics Agency (DLA) for Xolair 150 mg/ml syringes, valued at $11,605.50. This firm fixed-price delivery order, issued on September 23, 2025, with an ultimate completion date of October 15, 2025, represents a direct procurement without set-aside designation. The award is issued under DMS Pharmaceutical Group's existing...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a $1,547.40 firm fixed-price delivery order from the Defense Logistics Agency (DLA) on September 18, 2025, for XOLAIR 75 mg/0.5 mL syringes. The delivery order, which carries an ultimate completion date of October 9, 2025, was issued without a set-aside designation, allowing the company to compete directly in the open market. This award represents a discrete fulfillment...
- SPE2DB24D9238Indefinite Delivery Contract
- SPE2DB24D9238-SPE2DB25FDRCJDelivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a $9,284.40 firm fixed-price delivery order from the Defense Logistics Agency (DLA) on September 24, 2025, for XOLAIR 150 mg/ml syringes. The award, which carries no set-aside designation, is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, a $499.999 billion vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products and medical supplies for military health facilities worldwide. The delivery order is scheduled for completion by October 16, 2025, with performance taking place at the contractor's Park Ridge, Illinois location. This delivery order reflects DMS Pharmaceutical Group's established role as a critical supplier within the federal pharmaceutical supply chain, leveraging its long-standing relationship with the DLA to provide specialty medications and biologics to Department of Defense healthcare sites. XOLAIR (omalizumab), a monoclonal antibody used primarily for severe asthma and chronic urticaria treatment, represents the type of specialized pharmaceutical product the company routinely distributes through its DLA contract portfolio, which encompasses prescription drugs, biologics, auto-injectors, and other medical consumables supporting military medical operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.3k | 9/24/25 |